910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

T.K Choueiri,J.M.G Larkin,S.K Pal,R.J Motzer,B Venugopal,B.Y Alekseev,H Miyake,G Gravis,M.A Bilen,A Chudnovsky,K.A Ching,M Mariani,P.B Robbins,B Huang,A Di Pietro,L Albiges

doi:10.1093/annonc/mdz249.009

910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

T.K Choueiri, J.M.G Larkin + Show 14 more

Open Access

https://doi.org/10.1093/annonc/mdz249.009

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Oct 1, 2019
Citations: 29	License type: publisher-specific-oa

Affiliation: Brigham and Women's Hospital, Royal Marsden Hospital, City Of Hope National Medical Center, Memorial Sloan Kettering Cancer Center, University of Glasgow, Hamamatsu University School of Medicine, Emory University

#Research Grant #Funding Institution + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

910PD - Efficacy and biomarker analysis of patients (pts) with advanced renal cell carcinoma (aRCC) with sarcomatoid histology (sRCC): Subgroup analysis from the phase III JAVELIN renal 101 trial of first-line avelumab plus axitinib (A + Ax) vs sunitinib (S)

Full Text